Key Takeaway: Syndax Pharmaceuticals is set to showcase its late-stage programs and introduce new pipeline assets at an upcoming R&D event. Notably, the company is expanding its pipeline with SNDX-4321, a mutant-selective allosteric EGFR inhibitor aimed at addressing significant unmet needs in non-small cell lung cancer (NSCLC) patients. Additionally, SNDX-62122, a next-generation menin inhibitor, has been selected for development in myelofibrosis (MF) based on compelling preclinical results.
Price reaction · baseline $22.89 (2026-07-13 close) · hit pre-market · clean, no other SNDX news in the window
day 0 close · peak
+5.4%
day 1
+2.8%
day 3
-0.4%
Market Sentiment Analysis
POSITIVE FACTORS
Introduction of SNDX-4321 targeting NSCLC with unmet needs.
SNDX-62122 shows promise as a next-generation menin inhibitor.
Focus on late-stage programs indicates strong pipeline development.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+133%
120-day peak, hindsight
Typical move
5.3%
average across 8 past catalysts
Cash runway
~54 mo
Low dilution risk
Lead asset
entinostat
Phase 1 · Epithelial Ovarian Cancer
Full Press Release Details
– Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs – – SNDX-62122, a next-generation menin inhibitor, selected for development in MF, building on compelling preclinical results
Frequently Asked Questions
What is SNDX-4321?
SNDX-4321 is a novel, mutant-selective, allosteric EGFR inhibitor targeting NSCLC.
What condition is SNDX-62122 being developed for?
SNDX-62122 is being developed for myelofibrosis (MF).
What event will Syndax highlight its programs?
Syndax will showcase its late-stage programs at an upcoming R&D event.
What are the benefits of SNDX-4321?
SNDX-4321 aims to address significant unmet needs in NSCLC patient populations.